. In addition to being reproducible, simple and quick, ideal differentiation strategies would yield pure populations of cells in sufficient quantities to enable high-throughput screening and large-scale analyses. Thus, a major obstacle for using hPSCs to model disease remains the lack of reliable, efficient and scalable protocols to differentiate functionally mature adult cell types.
Blood vessels deliver oxygen and nutrients to all of the tissues and organs in the body. The two main cellular components of blood vessels are endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). Both ECs and VSMCs are required for vascular function, including blood pressure control, interactions with immune cells, and the uptake of nutrients. Consequently, these cells are involved in a variety of pathological dysfunctions, including the most common cardiovascular disease, atherosclerosis. So far, there exist two commonly used methods to induce vascular cell differentiation from hPSCs: embryoid body formation 7, 8 ; and monolayer-directed differentiation 9, 10 . Embryoid body formation results in differentiation of hPSCs into various cell types, including vascular cells, albeit inefficiently (1-5%; refs 7,11,12) . Moreover, embryoid body differentiation is often time consuming, with peak expression of endothelial genes occurring after 10-15 days 13 . Current monolayer differentiation methods offer increased efficiencies (5-20%) but depend on undefined supplements, co-culture 10, 14, 15 , heterogeneous cell aggregates 16 , or conditioned medium 9, 17 , or lack consistent yields of vascular cells 18 . Thus, improved methods would increase differentiation fidelity, efficiency and kinetics.
In mammalian development, vascular progenitors emerge from the lateral and posterior mesoderm 19 . Several studies describe the importance of canonical Wnt signalling in mesoderm commitment during embryogenesis 20 . For example, mice with impaired Wnt signalling lack mesoderm 21, 22 . Canonical Wnt signalling in hPSCs induces mesendoderm 23 , cardiogenesis 24 and the formation of vascular cells 16 . On the basis of previous reports [25] [26] [27] , we sought to develop a protocol for the differentiation of hPSCs to vascular cells. Here, we describe the rapid and efficient conversion of hPSCs into vascular cells using chemically defined conditions. Our protocol utilizes GSK3 inhibition and BMP4 treatment to convert hPSCs into mesodermal cells that when exposed to VEGF-A or PDGF-BB produced functional ECs or VSMCs.
RESULTS

Canonical Wnt activation and mesoderm induction by pharmacological inhibition of GSK3
Wnt signalling directs differentiation of hPSCs into mesoderm and GSK3β inhibition activates this pathway 16, 23 . However, smallmolecule inhibitors of GSK3 can promote either self-renewal or mesendodermal differentiation of hPSCs (refs 16,28,29) . We therefore attempted to identify selective GSK3β inhibitors that promoted efficient commitment of hPSCs towards mesoderm. A panel of GSK3 inhibitors was evaluated for their selectivity and potential to inhibit GSK3 and to activate Wnt signalling (Supplementary Table 1 ).
An in vitro competition binding assay against 96 protein kinases was performed to evaluate the specificity of GSK3 inhibitors, including 6-bromoindirubin-3 -oxime (BIO), CHIR99021 (CHIR; ref. 30 ), SB216763 (SB; ref. 31) and a Roche compound, CP21R7 (CP21; Supplementary Fig. 1A ). CP21 and CHIR were the most selective GSK3 inhibitors (Supplementary Table 2 ). CP21 also showed the highest affinity to GSK3β followed by CHIR ( Supplementary Fig. 1D ). These findings indicate that CP21 and CHIR are high-affinity, selective GSK3β inhibitors.
To examine the capacity of these compounds to activate canonical Wnt signalling, a dose-response assay was performed using a reporter cell line 32 with the luciferase gene expressed by a TCF/LEF promoter ( Supplementary Fig. 1B ). CP21, BIO and CHIR were able to potently activate canonical Wnt signalling with the highest activity at 3 µM (CP21, BIO) and 10 µM (CHIR). In contrast, SB, AR and MeBIO did not induce TCF/LEF luciferase expression (Fig. 1a) . The increase in TCF/LEF-luciferase activation by GSK3 inhibitors was not due to global transcriptional activation as measured in Gli-luciferaseresponsive reporter cells ( Supplementary Fig. 1C ). Furthermore, the compounds did not affect cell viability except BIO, which was toxic at concentrations above 3 µM ( Supplementary Fig. 1C,E) . Thus, CP21, CHIR and BIO were able to activate canonical Wnt signalling to similar levels, but given the toxicity of BIO we chose not to include this compound in subsequent experiments. Next, we analysed protein levels of β-catenin in hPSCs treated with CP21 and CHIR. Immunofluorescence staining revealed that CP21 and CHIR significantly increased total levels of intracellular β-catenin (Fig. 1b) . This result was confirmed by gene expression analyses (Fig. 1c) , wherein Wnt target genes were upregulated following CP21 and CHIR treatment of hPSCs. Thus, CP21 and CHIR potently and selectively inhibit GSK3 to activate canonical Wnt signalling.
We next investigated whether GSK3 inhibition with CP21 and CHIR in hPSCs would induce mesoderm. As BMP4 is also a potent inducer of mesoderm 33 , we tested BMP4 alone or combined with Wnt activation by CP21 and CHIR. Gene expression analyses revealed that BMP4 treatment with Wnt activation led to upregulation of genes associated with mesoderm, such as T, MIXL and EOMES (Supplementary Fig. 2A ). Immunostaining of CP21-and BMP4-treated cells showed high levels of BRACHYURY (T) expression that peaked at day three (Fig. 1d) . Conversely, OCT4 was downregulated. SOX17 was not detected, indicating that the cells were likely to be mesodermal (Fig. 1d) . Similar results were obtained using CHIR and BMP4 (Fig. 1d) . Thus, activation of Wnt signalling by GSK3 inhibition with CP21 or CHIR combined with BMP4 induced commitment of hPSCs towards mesoderm.
Efficient differentiation of mesodermal progenitors to endothelial cells or vascular smooth muscle cells
We assessed the ability of hPSC-derived mesoderm to undergo vascular lineage commitment using a chemically defined protocol consisting of three steps. First, hPSCs were plated as single cells at a density of 37,000 cells per square centimetre with the Rhokinase inhibitor Y-27632 (ref. 34); second, cells were differentiated to mesoderm using either CP21 or CHIR and/or BMP4; and third, they were treated with VEGF-A to induce ECs (ref. 16 ). At day five, EC differentiation was evaluated by analysing the expression of vascular endothelial cadherin (VE-cadherin, CD144). CD144
+ cells were readily detected in CHIR-and CP21-treated cultures, but were absent in controls ( Supplementary Fig. 2B ). Flow cytometric analysis of CD144 expression revealed that only BMP4 and CP21 or CHIR combined were capable of inducing high levels of expression, whereas treatment with BMP4 alone led to fewer than 10% CD144 + cells ( Supplementary Fig. 2C ). Additional analysis identified CP21 as the most potent compound ( Supplementary Fig. 2D ) with a concentration of 1 µM yielding up to 35% CD144 + cells, whereas CHIR induced CD144 expression most efficiently at a concentration of 6 µM. When either GSK3 inhibitor was used at its optimal concentration the yield of CD144
+ cells was equivalent ( Supplementary Fig. 2E ). We next combined VEGF-A treatment with forskolin for two days, as protein kinase A activation by cyclic AMP leads to an increase in vascular development 35 , followed by VEGF-A treatment alone for an additional four days ( Supplementary Fig. 2F ). We tested this strategy on several hPSC lines, including HUES9, SA001, BJ-RiPS and a commercially available induced PSC line 36, 37 . This protocol promoted the differentiation of hPSCs into endothelial cells with efficiencies between 61.8% and 88.8% (s.e.m. 3.1, n = 10 independent experiments) as assessed by flow cytometry of CD144 + cells (Fig. 2a,b  and Supplementary Table 4A ). CD144 + cells were further analysed for expression of EC-specific markers. Flow cytometry revealed that hPSC-derived ECs expressed KDR, CD31, CD34 and CD105. Expression of the haematopoietic lineage markers CD43 and CD45 was not detected (Supplementary Fig. 2G ). Immunostaining revealed that the cells were also positive for the EC markers vWF and PECAM1 (Fig. 2c) . Overall, these results demonstrate that GSK3 inhibition and BMP4 treatment followed by a brief period of VEGF-A and forskolin exposure and continued VEGF-A treatment is sufficient to rapidly and efficiently induce ECs from hPSCs (Fig. 2e) .
Interestingly, immunostaining revealed that in addition to ECs a small fraction of cells expressed the vascular smooth muscle marker smooth muscle actin (αSMA; Supplementary Fig. 2H ). We reasoned that by replacing endothelial inductive cues with factors that promote VSMC formation we might efficiently generate VSMCs. ActivinA and PDGF-BB have been shown to promote the formation of VSMCs (refs 38-40). Thus, we added ActivinA and/or PDGF-BB following mesoderm induction. Strikingly, this modification resulted in the formation of almost exclusively CD140b + (PDGFRB) cells with virtually no CD144 + cells detectable when ActivinA and PDGF-BB were used (Fig. 2a,b and Supplementary Fig. 2I,J) . The differentiation of CD140b
+ cells required either CP21 or CHIR and was not induced following treatment with BMP4 alone (Supplementary Fig. 2K ). The cells also expressed other markers of VSMCs, such as αSMA and myosin IIB (Fig. 2d) . Supplementary Fig. 3A ). This similarity is also reflected by the Pearson correlation coefficient for all expressed genes between primary and hPSC-derived ECs (r = 0.93) or primary and hPSC-derived VSMCs (r = 0.88). Of note, cultured primary cells do not perfectly mimic their in vivo counterparts.
To examine mesoderm commitment a time course of gene expression was plotted for representative genes from pluripotent cells, mesoderm, neuroectoderm, endoderm, endothelium and regionalization of the primitive streak ( Supplementary Fig. 3B ). These analyses revealed that pluripotent cell markers such as NANOG, UTF1 and SOX2 were rapidly downregulated. OCT4 expression was less rapidly downregulated and decreased by day 10. We observed a transient activation of the genes found in mesoderm, such as MIXL1, T (also known as BRACHYURY ), FGF4 and EOMES. With the exception of the endodermal marker SOX17, which was highly expressed at day five of EC differentiation, expression of markers associated with neuroectoderm or endoderm was not observed. Expression of SOX17 mimics the in vivo pattern found in the developing and adult vasculature 41 . We did not observe differentiation of trophectoderm or visceral endoderm, as ESX1 and SOX7 were undetectable. These data support the differentiation of hPSCs through a mesodermal intermediate into ECs or VSMCs.
We found that 2,955 genes were differentially expressed by at least tenfold between hPSCs, differentiated ECs, VSMCs and primary cells (Fig. 3a) . These genes were hierarchically clustered and analysed on the basis of Gene Ontology (GO) terms using the DAVID Bioinformatics Resource. The most prominently enriched gene sets included annotations for blood vessel development (GO:0001568, P < 10 −19 ) and cell adhesion (GO:0007155, P < 10 −10 ) for ECs, extracellular matrix organization (GO:0030198, P < 10 −11 ) and muscle organ development (GO:0007517; P < 10 −8 ) for VSMCs, and cell projection organization (GO:0030030; P < 10 −9 ), cell adhesion (GO:0007155, P < 10 −13 ) and the cell cycle process (GO:0007049; P < 10 −6 ) for hPSCs ( Fig. 3b ). We performed gene set enrichment analysis to find within all differentially expressed genes, over-or under-represented gene sets representative for biological processes. Only gene sets passing significance thresholds with a P value of 0.001 and a false discovery rate of 0.05 were selected as biological processes significantly over-or under-represented in hPSC-derived ECs, VSMCs, and primary cells versus hPSCs. Top over-represented biological processes for hPSCderived and primary ECs included endothelial cell differentiation (GO:0045446), angiogenesis (GO:0001525), endothelium development (GO:0003158) and blood vessel development (GO:0001568). For all VSMCs, the top upregulated biological processes were extracellular matrix (GO:0030198), collagen fibril organization (GO:0030199), regulation of smooth muscle cell migration (GO:0014911) and proliferation (GO:0048660). The most significantly downregulated processes in hPSC-derived ECs and VSCMs were gene sets for mitosis (GO:0007067) and chromosome segregation (GO:0007059) (Supplementary Table 3 and Supplementary Fig. 3C ).
In summary, transcriptome-wide expression analysis demonstrated that hPSC-derived ECs and VSMCs were highly similar to their respective primary cells.
hPSC-derived ECs and VSMCs exhibit a metabolomic profile similar to primary vascular cells
We performed metabolomic analysis by liquid chromatographytandem mass spectrometry of hPSC-derived vascular and primary cells. Of 106 metabolites, we detected 66 intracellularly (Supplementary Table 5 ). There was a strong correlation between metabolite levels in primary ECs and in hPSC-derived ECs (Spearman coefficient HUVEC versus hPSC EC = 0.96, HCAEC versus hPSC EC = 0.98, Fig. 3c,d ), and also between metabolite concentrations in primary VSMCs (UASMCs) and in hPSC VSMCs (Spearman coefficient = 0.92, Fig. 3c,d ). These similarities were seen across metabolite classes, including amino acids, amino-acid derivatives, nucleosides, organic nitrogenous compounds, aromatic acids, amine oxides, and other organic acids (Supplementary Table 5 ). In contrast, hPSCs had a distinct metabolic profile when compared with hPSC ECs (Spearman coefficient = 0.80) or hPSC VSMCs (Spearman coefficient AUSMC (contractile) versus hPSC VSMC (contractile) = 0.97, AUSMC (synthetic) versus hPSC VSMC (synthetic) = 0.97, Fig. 3c,d ). Thus, these analyses indicate that hPSC-derived vascular cells have metabolic profiles that closely resemble primary ECs and VSMCs.
hPSC-derived ECs and VSMCs exhibit mature functional properties
We sought to analyse the functional capabilities of hPSC-derived vascular cells. To determine the barrier function of hPSC ECs we measured impedance using an xCELLigence RT-CA system 42, 43 . The formation of a tight monolayer was observed by an increase in impedance within four hours after plating. Monolayer impedance reached a plateau, which was maintained for several days without major fluctuations (Fig. 4a) . Treatment with the vasoactive agent thrombin led to a rapid and reversible decrease in impedance 44 . Analysis of trans-endothelial electrical resistance (TEER) revealed that hPSC ECs showed TEER values similar to primary ECs (HUVECs). Treatment with the cytokines TNF-α, VEGF-A and IL1β led to disruption of the barrier tightness as revealed by a decrease in the TEER values (Fig. 4b) . We then analysed further in vitro functional features of hPSC ECs. The capacity of lipid uptake was monitored using fluorescently labelled acetylated LDL (Fig. 4c) .
To determine whether hPSC ECs respond to proinflammatory cytokines with a pro-adhesive phenotype, we challenged the hPSC ECs with TNF-α and IL-1β. Immunofluorescence analysis showed an increased expression of intracellular adhesion molecule-1 (ICAM1) on TNF-α treatment (Fig. 4d) . Flow cytometric analysis results confirmed the upregulation of ICAM1 on TNF-α and IL-1β stimulation (Fig. 4e) . We co-cultured hPSC ECs with leukocyte-like HL60 cells to examine cellular adhesion molecule-mediated tethering and capture 45, 46 . Remarkably, adhesion of HL60 cells was significantly enhanced when hPSC-derived ECs were stimulated with TNF-α (Fig. 4f) . Application of ICAM1-specific antibodies reduced adhesion of HL60 cells in a concentration-dependent manner suggesting that leukocyte adhesion was indeed mediated by ICAM1 (Fig. 4g) .
Next, we analysed the contractility of hPSC VSMCs by stimulation with vasoconstrictive drugs or cytokines ( Fig. 4h and Supplementary  Fig. 4A ). Calcium imaging revealed that endothelin1 and carbachol induced an increase in intracellular calcium levels. Treatment with atropine prevented carbachol-mediated calcium influx. Using a threedimensional collagen contractility assay, hPSC VSMCs contracted similarly to primary VSMCs when exposed to a vasoconstrictor (U46619; Fig. 4i and Supplementary Fig. 4B ). Thus, hPSC-derived VSMCs are capable of responding to vasoconstrictive stimuli exhibiting a key functional in vivo characteristic. Fold-change RFU to t = 1 (before treatment) at t = 50 s (maximum peak).
Columns show mean ± s.d. of 3 independent assays and data were evaluated using Student's t-test; * = P = 0.03. (i) Contractility assay on UASMCs and hPSC VSMCs with U46619 48 h after treatment. This graph shows one single experiment where control = 1 well and test = 2 wells per conditions. Deposition of extracellular fibronectin was analysed following treatment of hPSC VSMCs with increasing concentrations of TGF-β ( Supplementary Fig. 4C ). Interestingly, fibronectin deposition could be detected even in untreated cultures. As VSMCs produce TGF-β this is possibly due to autocrine TGF-β signalling 47 . Treatment with exogenous TGF-β led to a slight increase in fibronectin production. The addition of small molecules inhibiting TGF-β signalling (SB525334 or JQ1) prevented fibronectin production in the presence and absence of exogenous TGF-β. Thus, fibronectin deposition of hPSC VSMCs is mediated by TGF-β.
In summary, these findings show that hPSC-derived ECs and VSMCs demonstrate key mature functional properties.
hPSC (Fig. 5a,b) . Remarkably, when hPSC ECs were co-cultured with primary human brain vascular pericytes (hBVPs) both cell types arranged in highly organized structures with hBVPs tightly associated to endothelial tubes (Fig. 5c ). HBVPs cells seemed to envelope hPSC EC tubes (Fig. 5d ). These results demonstrate that hPSC ECs have angiogenic potential in vitro. To evaluate this potential in vivo, we used fibrinogen grafts in immunodeficient NOD-SCID mice 48 . We implanted either hPSC ECs alone, HUVECs and MSCs, hPSC ECs and MSCs, or hPSC ECs and hPSC VSMCs into the dorsal side of NOD-SCID mice and recovered the grafts for analysis after 14 days (except for hPSC ECs alone = 7 days) ( Supplementary Fig. 5) 
48
. Haematoxylin and eosin staining showed vessel-like networks in implants containing HUVECs and MSCs, hPSC ECs and MSCs, and hPSC ECs and hPSC VSMCs (Fig. 5g,i,k) . Of note, vessels contained numerous circulating red blood cells. Staining with an antibody against human CD31 revealed vessellike structures throughout the implants (Fig. 5h,j,l) . Thus, hPSC ECs are capable of contributing to patent, blood-containing vessel-like networks in vivo.
DISCUSSION
We report the rapid and efficient differentiation of hPSCs to ECs and VSMCs. GSK3β inhibition combined with BMP4 treatment enabled the commitment of hPSCs to mesoderm. Subsequently, differentiation was directed by treatment with VEGF-A for ECs or PDGF-BB and ActivinA for VSMCs. This in vitro differentiation pathway showed similarities to vascular development in vivo. For instance, Wnt signalling is required to induce primitive streak formation 20 , which then becomes committed lateral plate mesoderm by BMP4 signalling. These events were also observed during our in vitro differentiation protocol. Genome-wide expression analysis revealed transiently expressed gene clusters linked to mesoderm formation and further regionalization into lateral plate mesoderm. Subsequently, EC and VSMC formation was indicated by increased expression of genes associated with vasculogenesis. Importantly, our protocol produced ECs and VSMCs that closely resembled their primary counterparts. Comprehensive functional characterization of hPSC-derived vascular cells indicated a bona fide vascular phenotype. Taken together, these experiments confirm the identity and maturity of the hPSC-derived ECs and VSMCs and suggest that the cells could be used to faithfully model human disease.
Compared with other protocols that induce vascular cells from hPSCs, our approach provides several advantages. First, it occurs under chemically defined conditions in monolayer culture with low variability. Although a recently published report uses chemically defined conditions and starts with a monolayer culture, they observed considerable variation between experiments and starting cell lines and achieved efficiencies of only 10-30% (ref. 18 . As hPSC-derived ECs and VSMCs can be purified to near homogeneity by immunomagnetic cell sorting, the protocol is not only efficient but scalable. The method therefore represents a valuable tool for the application of stem cells in assays such as disease modelling or high-throughput screening where the availability of large numbers of defined cell types is a key prerequisite. This approach is likely to serve as a new standard for deriving ECs and VSMCs at scales relevant for drug discovery and regenerative therapies.
METHODS
Methods and any associated references are available in the online version of the paper. All cell lines were routinely tested for mycoplasma contamination and were negative throughout this study. SA001 and Gibco Episomal hPSC line have been tested with STR analysis, g-banding and Illumina SNP array (Omni Express). BJ-RiPSCs and Hues9 lines were sequenced and karyotyped. All hPSCs lines were maintained on hESC-qualified Matrigel (BD Biosciences)-coated dishes in mTeSR1 (StemCell Technologies). Cells were routinely passaged using Accutase (StemCell Technologies) and replated as small clumps of cells at a dilution of 1:10 to 1:15. For differentiation, hPSCs were dissociated using Accutase and plated on growth-factor-reduced Matrigel (BD Biosciences) at a density of 37,000-47,000 cells cm −2 (depending on the cell line) in mTeSR1 with 10 µM ROCK inhibitor Y-27632 (Calbiochem). After 24 h, the medium was replaced with Priming Medium, consisting of N2B27 medium (1:1 mixture of DMEM:F12 (1:1) with Glutamax and Neurobasal media supplemented with N2 and B27: all Life Technologies) with 1 µM CP21R7 (Roche) and 25 ng ml −1 BMP4 (R&D Systems). After three days, the priming medium was replaced by EC Induction Medium consisting of StemPro-34 SFM medium (Life Technologies) supplemented with 200 ng ml −1 VEGF (PeproTech) and 2 µM forskolin (Sigma-Aldrich). The Induction Medium was renewed after one day. On day six of differentiation, ECs were dissociated with Accutase and MACS-separated using CD144 MicroBeads (Miltenyi Biotec). For automated highthroughput processing, an autoMACSpro (Miltenyi Biotec) was used for sorting. One single hPSC gave rise to 17 hPSC ECs by day 6. For instance a T175 flask seeded at a density of 37,000 cells cm −2 contains about 55,000,000 cells by day 6. If the differentiation efficiency is 80% then approximately 44,000,000 would be CD144 positive. Positive sorted cells were replated on human fibronectin (Sigma-Aldrich)-coated dishes at a density of 25,000 cells cm −2 in EC Expansion Medium, consisting of StemPro-34 SFM supplemented with 50 ng ml −1 VEGF-A. EC Expansion Medium was replaced every other day. Cells at confluence were batch cryopreserved before they were routinely used for assays. Experiments described in this manuscript were performed with hPSC ECs at passage 4. At that point (p4) one single hPSC gave rise to 64 hPSC ECs. hPSC ECs maintained EC identity at least up to passage 8.
For VSMC differentiation, the medium was replaced on day four by VSMC Induction Medium, consisting of N2B27 medium supplemented with 10 ng ml −1 PDGF-BB (PeproTech) and 2 ng ml −1 ActivinA (PeproTech). The medium was exchanged every 24 h. On day six, cells were dissociated using Accutase and plated at 35,000 cells cm −2 on gelatin-coated wells in N2B27 supplemented with 10 ng ml −1 PDGF-BB and expanded for another 5-7 days to obtain synthetic VSMCs. To promote a contractile VSMC phenotype, cells were plated on collagencoated wells (Biocoat, BD Bioscience) in N2B27 containing 2 µg ml −1 heparin (Stem Cell Technologies) and 2 ng ml −1 ActivinA. The experiments described in this manuscript were performed with hPSC VSMCs at passage 4. hPSC VSMCs maintained VSMCs identity at least up to passage 8. A step-by-step protocol describing the culture of hESCs and the differentiation of hPSC ECs and hPSC VSMCs can be found at Nature Protocol Exchange 51, 52 . 53 , followed by antibiotic selection. For reporter assays, 40,000 TCF/LEF-luciferase reporter cells or Gli-luciferase reporter cells as controls were seeded into 24-well plates. After 24 h, GSK3 inhibitors were added to cells at different concentrations and luciferase activity was measured using One-Glo (Promega) after 24 h of inhibitor treatment. For toxicity evaluation of GSK3 inhibitors, unlabelled PA-1 cells were plated in the same way as reporter cells. The relative cell growth was measured with CellTiter Glo (Promega) after 24 h of inhibitor treatment.
RNA extraction, cDNA synthesis and RT-qPCR. Total RNA from human cell lines was extracted with Trizol (Life Technologies) and purified using the RNeasy mini kit (Qiagen) according to the manufacturer's instructions. RNA yield was determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). Total RNA (1 µg) was converted to cDNA using the Superscript First-Strand kit (Life Technologies). Quantitative PCR (qPCR) was done using SYBR Green (Life Technologies) or TaqMan Gene Expression Master Mix (Life Technologies) and detection was achieved using the ViiA7 thermocycler (Applied Biosystems). Primer sequence and Taqman probe references are listed in Supplementary Tables 6 and 7 . Expression of target genes was normalized to reference gene 18s. Fold regulation to day 0 was calculated using the ddCt method. 
Immunocytochemistry and flow cytometry. For immunocytochemistry cells
were washed once with PBS and fixed in 4% paraformaldehyde (PFA) for 10 min. The cells were then blocked with 10% normal donkey serum in PBS (Blocking buffer) for 45 min. When probing for an intracellular antigen, 0.1% Triton-X was included in the blocking buffer. The cells were then incubated with the primary antibodies (see Supplementary Table 8A ) in 5% normal donkey serum in PBS overnight at 4 • C. After three washes with PBS, cells were incubated in 1% BSA in PBS containing secondary antibodies (see Supplementary Table 8B ) and DAPI. Cells were washed three times with PBS. Images were acquired with a fluorescence microscope (Axiovert 200) and images were analysed using ImageJ.
For flow cytometry analysis, cells were dissociated with Accutase. Single-cell suspensions were subsequently incubated in growth medium at 37 • C for 1 h before staining. All FACS antibodies were directly labelled and obtained from BD Pharmingen. Stainings were performed according to the manufacturer's instructions and analysed using a Guava easyCyte flow cytometer (Millipore). The FACS antibodies used in this study are listed in Supplementary Table 8C .
Genome-wide gene expression analysis. Total RNA from cells was extracted using the RNeasy Mini kit combined with DNase treatment on a solid support (Qiagen). RNA quality assessment and quantification was performed using microfluidic chip analysis on an Agilent 2100 bioanalyser (Agilent Technologies). Five micrograms of total RNA was reverse transcribed using the Roche cDNA Synthesis System. After silica-adsorption column purification, double-stranded cDNA was labelled with Cy3 using the Roche NimbleGen One Color DNA Labeling Kit. NimbleGen 12 × 135 K gene expression microarrays (100718_HG18_opt_expr) were hybridized with 4 µg of Cy3-labelled cDNA for 16 h at 42 • C and were washed and dried according to the manufacturer's instructions. Microarray data were collected by confocal scanning using the Roche NimbleGen MS200 Microarray Scanner at 2 µm pixel resolution (Roche NimbleGen). NimbleGen probe intensities were subjected to robust multi-array analysis (RMA), background correction and quantile normalization as implemented in the NimbleScan Software, version 2.6 (Roche NimbleGen). Probe level signal intensities were summarized into gene calls and log 2 -transformed. Gene Ontology (GO) term analysis of gene lists was performed using DAVID Bioinformatics Resource (http://david.abcc.ncifcrf.gov). Gene Set Enrichment Analysis was applied to the data on the basis of the BROAD Institute algorithm (http://www.broadinstitute.org/gsea). Log 2 fold changes were used to rank the genes and to determine the enrichment of genes in gene sets derived from 3591 Gene Ontology (GO) terms (http://www.geneontology.org). For all GSEA analyses, 1,000 phenotype permutations were performed to assess the significance of the enrichment. Gene expression heat maps were generated using Tibco Spotfire 3.1.0 (Tibco Software) or the R software for statistical computing and graphics (http://www.r-project.org). The microarray data from this study have been deposited at the NCBI Gene Expression Omnibus 6 (http://www.ncbi.nlm.nih.gov/geo) under the accession numbers GSE52044 and GSE59326.
Metabolite profiling. HUVECs, UASMCs (Lonza), hPSC ECs and hPSC VSMCs (all passage 4) were seeded in 6-well plates and cultured in StemPro34 medium. Once confluent, cells were starved overnight in basal medium. The medium was siphoned off and the plate immersed in high-performance liquid chromatography (HPLC)-grade water, the water decanted and aspirated, and then the culture plate carefully placed on the surface of liquid nitrogen in a liquid nitrogen-resistant basin for 15 s to quench cellular metabolic activity. Next, 2 ml of extraction medium (75% 9:1 methanol/chloroform, 25% H 2 O) was poured into each well. After 15 s, 1.5 ml was aspirated into respective labelled sample tubes, and 0.5 ml was aspirated from each well into collective pooled lysate tubes. Lysates were then centrifuged (16,873g , 4 • C for 10 min), and 200 µl of the supernatant was aliquoted into conical Eppendorf tubes and labelled isotope standards (L-phenylalanine-d 8 and L-valined 8 ) were added to the supernatants. Samples were then dried down on a speedvac concentrator (Thermo Scientific) and resuspended in 100 µl of acetonitrile/water (50:50 v/v) before injection. Sample injection volume was 10 µl.
Liquid chromatography-tandem mass spectrometry (LC-MS) data were acquired using a 4000 QTRAP triple quadrupole mass spectrometer (Applied Biosystems/Sciex) that was coupled to a multiplexed LC system comprised of a 1200 Series pump (Agilent Technologies) and an HTS PAL autosampler (Leap Technologies) equipped with two injection ports and a column selection valve, as previously reported 54 . The pump was configured for hydrophilic interaction chromatography (HILIC) using a 150 × 2.1 mm Atlantis HILIC column (Waters) and mobile phase (mobile phase A: 10 mM ammonium formate and 0.1% formic acid, v/v; mobile phase B: acetonitrile with 0.1% formic acid, v/v). Multiplexing was used to enable the measurement of 106 metabolite transitions. The samples were injected directly onto a 150 × 2.1 mm Atlantis HILIC column (Waters) that was eluted at a flow rate of 250 µl min −1 with initial conditions of 5% mobile phase A and 95% mobile phase B followed by a 10.5 min linear gradient to 60% mobile phase A. MS analyses were carried out using electrospray ionization (ESI) and multiple reaction monitoring (MRM) scans in the positive ion mode. Declustering potentials and collision energies were optimized for each metabolite by infusion of reference standards before sample analyses. The dwell time for each transition was 30 ms, the ion spray voltage was 5 kV, and the source temperature was 450 • C. Internal standard peak areas were monitored for quality control and individual samples with peak areas differing from the group mean by more than two standard deviations were reanalysed. Metabolite concentrations were determined using the standard addition method. This method allows profiling of amino acids, amino-acid derivatives, urea cycle intermediates, nucleotides and other positively charged polar metabolites. Formic acid, methanol, chloroform, ammonium acetate, LC-MS-grade solvents and L-valine-d8 were purchased from Sigma-Aldrich. L-phenylalanine-d8 was purchased from Cambridge Isotope Laboratories.
MultiQuant software (Version 2.1.1; Applied Biosystems/Sciex) was used for automated peak integration and metabolite peaks were manually reviewed for quality of integration and compared against a known standard to confirm identity. For all isotope measurements using these LC-MS methods, peak areas were greater than two orders of magnitude above the lower limit of quantification (as defined as a discrete peak tenfold greater than noise) and fell well within the linear range of the dose-response relationship. Data were normalized relative to pooled plasma reference samples that were analysed in the sample queue after sets of 10 study samples. All experiments were done in triplicate.
Calcium imaging. At day 11 of differentiation, VSMCs were seeded on collagencoated wells at 50,000 cells cm −2 in N2B27 containing 2 µg ml −1 heparin and 2 ng ml −1 ActivinA. After 48 h, cells were pretreated with 1 mM atropine (Sigma) or an equal amount of ethanol (atropine solvent) for 45 min at 37 • C. Then, cells were incubated for 15 min with calcium dye and calcium imaging was performed. Relative fluorescence units (RFU) were measured every second. After 15 s, cells were treated with vehicle, 1 mM carbachol (Sigma) or 0.1 µM endothelin1 (Sigma). For calculation of fold change, average values of the first 14 data points were used as reference (t0).
Fibronectin production. At day 12 of differentiation, hPSC VSMCs were seeded in N2B27 containing 10 ng ml −1 PDGF-BB at 37,500 cells cm −2 on gelatin-coated wells. After 24 h, the medium was changed to N2B27 with 10 ng ml −1 PDGF-BB supplemented with DMSO (control), 10 µM SB525334 (Tocris), or 10 µM JQ1 (Biovision) and indicated concentrations of TGF-β (Peprotech). After 24 h, cells were washed with PBS, fixed with 4% PFA for 10 min at room temperature, and immunofluorescence staining of deposited Fibronectin (no permeabilization step) was performed.
Tube formation. Four hundred microlitres of Matrigel (BD Matrigel Basement
Membrane Matrix Growth Factor Reduced, Phenol Red Free) was aliquoted into each well of a 12-well plate and incubated for 30-60 min at 37 • C to allow the gel to solidify. HPSC ECs prestained with CellTracker (Molecular Probes/Life Technologies) and 80,000 ECs were then seeded onto the matrix and cultured for 24 h at 37 • C until image acquisition. To test the impact of the angiogenesis inhibitors L-sulphoraphane (Sigma S6317) and anti-VEGF monoclonal antibody (human VEGF 165 antibody; R&D Systems) on tube formation, the ECs were pre-incubated with inhibitors at indicated concentrations for 45-60 min at 37 • C. Eighty thousand cells were then added to the Matrigel-coated well and cultured for 24 h at 37 • C. Cells were fixed with 2% PFA for 10 min and stained with Diff-Quick II (Medion Diagnostics) for 2 min. To measure the extent of tube formation, micrographs covering an area of 32 mm 2 were acquired in each well using an inverted microscope (Axiovert 200, ×5 objective). The acquired images were analysed using a customdeveloped image analysis algorithm (see below).
Quantitative image analysis of tube formation. The capacity to form tubular structures on a two-dimensional Matrigel surface was quantified using a customdeveloped image analysis algorithm implemented in the Developer XD software package (Definiens). Briefly, areas in the image containing cells were identified from background by multiple threshold segmentation. The segmented cell area was skeletonized to obtain the central line of the tubular structure. The resulting linear network was classified into linear segments and nodes, defined as the convergence of three or more segments. Large convex cell areas were classified as area of confluence. The tube formation capacity was parameterized by the total segment length per image (in pixels) and the number of nodes per image. No large area of confluence was observed. The hBVPs used for the experiments were between passage 3 and 4. All cultureware (BD Falcon) was coated with rat tail collagen type I solution (BD Biosciences) at 10 µg cm −2 . HBVPs were grown in Pericyte Medium (ScienCell Research Laboratories). For the functional tube formation and association assays, the HPSC ECs and the hBVPs were grown using an in vitro angiogenesis kit from AMS Biotechnology. Immediately before seeding for functional assays, hBVPs and HPSC ECs were stained red and green, respectively, using CellTracker dyes (Molecular Probes/Life Technologies) according to the manufacturer's instructions. Cells were grown in StemPro34 SFM (Life Technologies) supplemented with 50 ng ml −1 rhVEGF-A (Peprotech). For the experiment, 2 × 10 4 hPSC ECs cm −2 and 2 × 10 4 hBVPs cm −2 were cultured alone or together, with or without 100 ng ml −1 hPDGF (R&D Systems), for 24 h in the incubator.
Uptake of Dil-Ac-LDL. Cells were incubated with 2.5 µg ml −1 DiI-Ac-LDLAlexa597 (Molecular Probes/Life Technologies) in StemPro34 medium for 4 h at 37 • C. Thereafter, cells were washed three times with PBS and fixed with 4% PFA for 10 min. DNA was counterstained with DAPI. Cellular uptake of DiI-Ac-LDL-Alexa 597 was visualized with a fluorescence microscope (Axiovert 200).
Real-time impedance measurement and thrombin stimulation. Cell growth behaviour was continuously monitored every 15 min for 2 days using a Real Time Cell Analyzer (xCELLigence, Roche). For time-dependent cell response profiling, 100 µl of cell culture medium was added to the fibronectin-coated 96-well E-plates to obtain background readings followed by the addition of 100 µl of cell suspension. The E-plates containing the cells (20,000 cells cm −2 ) were incubated at room temperature for 10 min and placed on the reader in the incubator for continuous recording of impedance as reflected by cell index (CI). The cells were monitored every 15 min before and every 2 min after thrombin addition. The CI curves are shown as the average of 5 replicates ± s.d. Cells were treated with 20 U ml −1 thrombin. All data were normalized to the first impedance background measurement.
Trans-endothelial electrical resistance (TEER). HUVECs and HPSC ECs were
seeded at a density of 1 × 10 6 cells ml −1 on 24-well cell culture inserts (0.4 µM pore size, Falcon) coated with fibronectin. Cells were grown for 72 h in EGM-2 medium (Lonza). The medium was then changed to starvation medium (basal EBM medium + 0.5% FBS; Lonza) with or without vascular permeability factors (100 ng ml −1 TNF-α and IL-1β; Peprotech, 100 ng ml −1 VEGF-A, Aldevron) for 30 h. Transendothelial electrical resistance was recorded using the Endohm for 6 mm Culture Cup (World Precision Instruments). This experiment was performed in triplicates for each condition and repeated 3 times. Results are depicted as the steady-state TEER values with blank filter subtracted.
Adhesion molecule expression and adhesion of leukocyte-like cells to ECs.
Adhesion molecule expression was also determined in a cell-based ELISA. Here, hPSC ECs (2 × 10 5 cells per well) were seeded and grown in 96-well microtiter plates in 100 µl of EGM-2 medium (Lonza) until confluence (2-3 days). They remained either unstimulated or were stimulated with TNF-α (0.1-1 nM) for 24 h at 37 • C. Afterwards cells were washed with PBS and fixed with 2% PFA dissolved in PBS (pH 7.5). After a blocking step with sheep serum (20 min), cells were incubated for 1 h at 37 • C with a mouse anti-human VCAM1 (clone 1.4C3, Sigma), mouse antihuman ICAM1 (clone BBIG-I1; R&D Systems) or mouse anti-human E-selectin (BBIG-E4; R&D Systems) diluted in PBS + 0.01% BSA. A biotinylated sheep antimouse IgG (Amersham) was used for the detection of the bound primary antibody, followed by the addition of a preformed streptavidin-biotinylated horseradish peroxidase complex. Peroxidase activity was detected using TMB (KPL, A seraCare Company, Cat. 50-76-00) substrate solution. Attenuance was measured at 450 nm with the use of a 96-well microtiter plate reader (Molecular Devices, Versa max).
To analyse the adhesion of HL60 cells to ECs, Calcein-AM (Life Technologies)-labelled HL60 cells 55 at a dilution of 150,000 cells per well were co-incubated with the ECs for 1 h at 37 • C. After non-adherent HL60 cells were removed by washing with PBS, the cells were either fixed with PFA for immunofluorescence staining or lysed with NP-40 (Fluka) and the fluorescence was measured in a spectrofluorometer (Spectramax Gemini XS, Molecular Devices). In some experiments the ECs were pretreated with a neutralizing anti-ICAM-1 monoclonal antibody (clone 15.2; SouthernBiotech) 15 min before TNF-α stimulation.
Fibrinogen plug assay. Animal procedures were performed in accordance with an IACUC-approved protocol reviewed by the Subcommittee on Research Animal Care (SRAC) at Massachusetts General Hospital and consistent with the NIH guidelines for laboratory animal usage. Twenty male (5 per condition) 8-week-old NOD-SCID mice (Jackson Laboratories) were used. The implants were prepared following the protocol described in ref. 48 . The matrix was prepared by dissolving 2.5 mg ml −1 of bovine fibrinogen (Sigma-Aldrich) in basal EGM-2 (Lonza) and filtered through a 0.22 mm syringe filter (Millipore). HUVECs or hPHPSC ECs were mixed in a 1:1 ratio with primary MSCs (Lonza) or hPSC VSMCs and resuspended in the fibrinogen solution at a final concentration of 10 million cells ml −1 . Mice were anaesthetized with 1 g of 2,2,2-tribromoethyl alcohol dissolved in 1 ml of tert-amyl alcohol and diluted in 19 ml of PBS. Then two sites of injections were shaved, sterilized with betadine (Thermo Fisher Scientific) and washed with alcohol. Right before injection, 5% FBS and 6 µl of a thrombin solution (50 U ml −1 ; SigmaAldrich) were added to 300 µl (=3 million cells) of the fibrinogen-cell mixture. This solution was then immediately injected subcutaneously into the dorsal flank of the mouse. Two implants were injected per animal. Mice were returned to their cage for recovery about 5 min after injections to ensure proper polymerization of the implants. Three million hPSC ECs without any stromal cell type per implant were injected as the control. Experimenters were not blinded to the different experimental conditions. Implants were recovered after 14 days, except for the negative control, which was collected on day 7. Explants were placed in individual wells of a 12-well plate and imaged with an Axio Zoom V16 stereomicroscope (Zeiss). They were then fixed in 4% PFA for 1 h and then 0.4% PFA overnight. Both incubations were done at 4 • C. Samples were then washed and kept in PBS at 4 • C until they were embedded in paraffin and cut in 5 µM sections by C. MacGillivray at the HSCRB Histology Core facility. Haematoxylin and eosin staining was performed on even-numbered slides following a standard protocol. Odd-numbered slides were stained with a human specific CD31 antibody. Paraffin sections were rehydrated according to a standard protocol and boiled for 45 min in citrate buffer for antigen retrieval. After a quick rinse in distilled water, slides were treated with 3% hydrogen peroxide for 15 min and rinsed again. The primary antibody was diluted 1:50 in 3% horse serum and incubated at 4 • C overnight. The next day slides were washed 4 times in PBS for 15 min each and the secondary antibody (HRP-conjugated anti-mouse) diluted 1:500 was added for 30 min at room temperature. After 4 × 15-min-long PBS washes, slides were incubated for 30 min with the ABC solution (DAB kit, Dako), washed again and incubated with DAB substrate following the manufacturer's instructions. Slides were then mounted and imaged using a Duel head microscope (Olympus) and the Cellsens software (Olympus).
Statistical analysis. Statistical analyses were performed using Student's t-test and data were reported as mean ± s.d. or standard error of the mean. Statistical significance was assumed when P < 0.05. Spearman's rank correlation coefficient was used to detect statistical dependence between cell metabolite levels for the non-parametric metabolomic data. No samples or data were excluded from the analysis. No power calculation was performed to determine the number of samples required to achieve statistical significance. No randomization was used to determine how mice or samples have to be allocated in different experimental groups. No experiment was done blinded to the experimenter.
Reproducibility of experiments.
The luciferase assay was repeated 5 times independently at Roche. HPSCs ECs and hPSCs VSMCs were conducted 10 and 16 times respectively (Fig. 2a) The qPCR in Fig. 3c shows the mean of 3 independent experiments with samples from 3 wells of a 12-well plate each time. The microarray experiment ( Fig. 3 and Supplementary Fig. 3 ) was performed once with one biological replicate for endothelial differentiation at day 0-10, and one biological replicate for HSVECs, HAVSMCs and HPVSMCs. For the other microarray samples three biological replicates were analysed. The metabolomics experiments (Fig. 3) was conducted only one time with biological triplicates for each cell type. The impedance-based monitoring of hPSC ECs monolayer culture (Fig. 4a) was repeated 4 times in the laboratory with 8 technical replicates each. The TEER experiment (Fig. 4b) was repeated 3 times independently for a total of 9 Transwells per condition except the untreated one where n = 7 Transwells only. Adhesion assay was repeated 3 times in the laboratory (Fig. 4c-g ). The contractility experiment shown in Fig. 4h was repeated 3 times independently in the laboratory whereas the one in Fig. 4i was conducted only once with 2 wells per condition (except control n = 1 well). The tube formation assay in Fig. 5a was repeated 10 times and the effect of antiangiogenic molecules was measured in 3 independent experiments (Fig. 5b) . Coculture experiments of hPSC ECs with hBVPs were repeated 3 times. The in vivo experiment was conducted once with 5 NOD-SCID mice per condition and 2 implants per mouse (=10 implants per conditions). 
